Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

Use of a pMDI with a holding chamber is noninferior to nebulization for delivering salbutamol in children with asthma exacerbations.

The FDA has removed the REMS program requirements for embryofetal toxicity risk from all endothelin receptor antagonist medications.

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

The FDA published over 200 response letters sent as replies to drug and biological product applications in order to increase transparency.

Patients with severe asthma who initiate biologics may reduce their risk for oral corticosteroids (OCS)-related new-onset adverse outcomes.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Increased risk for all-cause and CVD mortality in OSA may be linked to a severe phenotype marked by objective excessive daytime sleepiness.

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

The likelihood of antiviral prescribing and dispensing among patients with influenza varied by care setting, patient age, and underlying medical conditions.

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Hospital staffing shortages are expected as applicants from foreign countries are unable to get visas under the Trump administration.